Toward the Development of a Bronchoscope With a Dedicated O2 Channel ?

NCT ID: NCT01963377

Last Updated: 2013-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Feasibility of using an extra bronchoscopic channel for supplementation of oxygen will be studied by comparing O2-supplementation by nasal cannulae versus O2-supplementation through aspiration channel of the bronchoscope.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Comparison of O2 administration using bronchoscope versus nasal cannulae in normal volunteers.

This study will compare partial pressure of oxygen measured in capillary blood (PcO2) at various O2 flow from 0 to 2 and 4 l/min administered using nasal cannulae or bronchoscope. During bronchoscopy, oxygen will be administered throughout the aspirating channel of the scope which extremity will be positioned at mid-tracheal level. After local anesthesia of the airways using lignocaine spray 10% and solution 1%, the bronchoscope will be introduced in seated position using a mouthpiece and placed at mid-tracheal level. Arterial O2-pressure sampled at the earlobe will be measured after incremental O2-supplementation from 0 to 2 and then 4 l/min using a nasal cannula or the aspirating channel of the bronchoscope. At each flow rate, capillary O2-pressure will be measured after 2 minutes. Between each condition of O2-supplementation there will be a pause of 5 minutes of room air breathing. The order of O2-supplementation condition will be selected at random. The whole bronchoscopic procedure should then last about 15 minutes. Additional doses of lignocaine 1% will be instilled in the trachea as requested and O2 saturation and heart rhythm will be monitored continuously during the procedure. Since the subjects are probably able to perceive additional flows in the nose and/or trachea and this may affect the pattern of breathing and the results, air at similar flow rate will be added in the nasal cannulae when O2 is administered using the bronchoscope channel and vice versa such that the subject will be blinded to the way O2 is administered.

This study should allow to demonstrate higher values of capillary O2-pressure during bronchoscopic administration of O2 than when using nasal cannulae. As shown by a recent meta-analysis, partial pressure of O2 measured in capillary blood from the arterialized earlobe (PcO2) is lower than the arterial value but this factor is not important in the present study since it will concentrate on differences in PO2 between the two conditions at similar O2 flow rates that are not affected by this limitation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchoscopy O2-supplementation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

bronchoscopy O2-supplementation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1. Nasal Cannulae / 2. Bronchoscope channel

Supplementation of O2 through will take place first through the aspiration channel of the bronchoscope, in second phase of the study O2-supplementation will be done through nasal cannulae.

Group Type EXPERIMENTAL

O2 through nasal cannulae

Intervention Type DEVICE

supplementation of O2 through nasal cannulae during bronchoscopy

O2-channel

Intervention Type DEVICE

supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy

1. Bronchoscope channel / 2. Nasal Cannulae

Supplementation of O2 through will take place first through nasal cannulae, in second phase of the study O2-supplementation will be done through the aspiration channel of the bronchoscope.

Group Type EXPERIMENTAL

O2 through nasal cannulae

Intervention Type DEVICE

supplementation of O2 through nasal cannulae during bronchoscopy

O2-channel

Intervention Type DEVICE

supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

O2 through nasal cannulae

supplementation of O2 through nasal cannulae during bronchoscopy

Intervention Type DEVICE

O2-channel

supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy subject

Exclusion Criteria

* younger than 18 years old
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Saint Pierre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Vincent Ninane

Head of Department Pulmonology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vincent Ninane, Prof., MD

Role: PRINCIPAL_INVESTIGATOR

CHU St. Pierre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU St. Pierre

Brussels, BHG, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AK/12-11-90/4190

Identifier Type: OTHER

Identifier Source: secondary_id

B076201215478

Identifier Type: -

Identifier Source: org_study_id